IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

<h4>Background</h4>To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIF...

Full description

Bibliographic Details
Main Authors: Vijayaprakash Suppiah, Silvana Gaudieri, Nicola J Armstrong, Kate S O'Connor, Thomas Berg, Martin Weltman, Maria Lorena Abate, Ulrich Spengler, Margaret Bassendine, Gregory J Dore, William L Irving, Elizabeth Powell, Margaret Hellard, Stephen Riordan, Gail Matthews, David Sheridan, Jacob Nattermann, Antonina Smedile, Tobias Müller, Emma Hammond, David Dunn, Francesco Negro, Pierre-Yves Bochud, Simon Mallal, Golo Ahlenstiel, Graeme J Stewart, Jacob George, David R Booth, International Hepatitis C Genetics Consortium (IHCGC)
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-09-01
Series:PLoS Medicine
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21931540/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21931540/?tool=EBI

Similar Items